Crossmark

Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses

Crossref DOI link: https://doi.org/10.1038/s41541-025-01349-w

Published Online: 2025-12-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ko, Kwang Hyun

Lee, Seung-Hwan

Choi, Young-Ho

Kang, Soon Myung

Yang, Hyun-Suk

Lee, So Min

Jo, Eun Bi

Bae, Hyun Shik

Hong, Seung-Beom

Kim, Dong-Ho

Cha, Seung Bin
Funding

Funding for this research was provided by:

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2025-02213626)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2025-02213626)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)

Korea Drug Development Fund, funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare of the Republic of Korea (RS-2024-00337146)
License Information

Text and Data Mining valid from 2025-12-23

Version of Record valid from 2026-01-27
More Information

Article History

Received: 9 July 2025

Accepted: 6 December 2025

First Online: 23 December 2025

Competing interests

: D.-H.K. is the Chief Executive Officer of NA Vaccine Institute. The remaining authors are employees of the institute. All authors declare that they have no competing interests.

Document is current

Any future updates will be listed below